Successful Withdrawal of Omalizumab in a Patient with Severe Asthma: Free IgE as a Possible Biomonitor

Abstract

To date, the pharmacological activity and clinical benefits of omalizumab have been well described, however several questions still remain unanswered, such as the moment to withdraw the drug as well as the possible biological markers that may be useful to do so. In the present case report, we describe our experience with our dose-reduction protocol in a middle-aged patient and elucidate the usefulness of free IgE levels.